Rapid Commercialization Partners

What Rapid Commercialization Partners does

Rapid Commercialization Partners (RCP) is a Cambridge, Massachusetts-based biotech commercialization consulting firm founded in 2020 and operating as a woman-owned business enterprise. The company provides fully operational, cross-functional commercial teams to clinical-stage biotech, private equity, and venture capital clients, with particular depth in rare disease and gene therapy therapeutics. Its core methodology is the registered ReCiPe™ framework, a five-pillar operational philosophy (Rapid, Evidence-based Commercialization, Insights, Planning, and Execution) applied across the commercialization continuum from pre-clinical through Phase III.

RCP delivers services spanning market assessment, commercial strategy, market access, pricing and reimbursement, medical affairs, diagnostics, and launch execution, serving both biotech companies and PE/VC portfolio companies seeking to accelerate time to market and maximize asset valuation. The firm leverages an alliance ecosystem of strategic partners (Virdis Group, Value Genome, Orphan Now, OrphanDC, LGA, Ubie Health, and others) to extend capabilities across executive search, European rare disease operations, LATAM clinical development, and AI-powered patient engagement. The senior team carries 125+ years in rare disease and 30+ years in gene therapy, with prior leadership experience at Alexion, PTC Therapeutics, and Novartis Gene Therapies.

The revenue model is professional services: milestone-driven, quote-based engagements where RCP acts as a fractional extension of client commercial organizations. Pricing is not publicly disclosed; the firm notes that fees are small relative to typical launch-phase commercial spend. Distribution is direct, relationship-led sales executed by the CEO and executive team, supplemented by content marketing, referral networks, and a dedicated Private Market Practice targeting PE/VC-backed biotech. The firm maintains no public funding history and operates with 1-10 employees.

Name

Rapid Commercialization Partners

Legal name

Rapid Commercialization Partners Inc.

Website

https://rcpbio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Rapid Commercialization Partners is a Cambridge, MA biotech consulting firm providing fractional cross-functional commercial teams to clinical-stage biotech and PE/VC firms, with specialized expertise in rare disease and gene therapy launch strategy and execution via its ReCiPe™ methodology.

Ownership category

akta.pro rank

Product category

Biotech Commercialization Consulting

NAICS

Other Scientific and Technical Consulting Services (54169), Management Consulting Services (54161)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)

Keywords

• Biotech commercialization consulting
• Rare disease launch
• Gene therapy consulting
• Market access strategy
• Clinical-stage biotech

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Commercial Strategy and Consulting Services: RCP generates revenue through professional services engagements where they provide fully operational, cross-functional commercial teams to biotech clients. The company acts as an extension of client organizations, delivering commercialization strategy, planning, and execution services. Engagements are milestone-driven with predefined timelines and specific exit criteria.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

RCP provides fully operational, cross-functional commercial teams to clinical-stage biotech companies on a fractional, embedded basis, executing commercialization strategy from market assessment through launch readiness. The firm specializes in rare disease and gene therapy assets, applying its ReCiPe™ methodology to accelerate timelines, optimize valuation, and reduce launch risk. Engagements are milestone-driven, with knowledge transfer back to the client organization as internal capabilities are built.

Product overview

Rapid Commercialization Partners (RCP) is a consulting services firm (not a software product company) that provides end-to-end strategic commercial planning and execution services for clinical-stage biotech companies. Their primary offering is the ReCiPe™ methodology, which serves as their operational framework. Services span across the commercialization continuum from pre-clinical through Phase III, covering market assessment, strategic planning, market preparation, execution, and optimization. The company operates as a fractional extension of client organizations, providing multidisciplinary teams of seasoned commercial executives to help biotech companies prepare for and execute product launches in rare disease and gene therapy therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

• ReCiPe™: An operational philosophy (Rapid, Evidence-based Commercialization, Insights, Planning and Execution) that serves as the basis for everything RCP does. It is a set of principles that can be applied at any point along the commercialization continuum.

Products and services

• ReCiPe™ Methodology
• Commercial Strategy and Execution Services
• Rare Disease and Gene Therapy Commercialization Services
• Private Markets / PE & VC Portfolio Services

Quantifiable outcome

• RCP fees are small compared to typical commercial spend during launch phases, with significant value delivered relative to investment

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Ten partnerships are on record, tiered core and minor.

• Virdis GroupcoreStrategic or Co-development PartnerGlobal Life Science executive search and organizational consultancy with offices in Oxford (UK), Lausanne (Switzerland), Boston (MA), and Barcelona (Spain). Provides talent identification and hiring services for executive to board-level roles across R&D and Commercial functions with particular expertise in market and payor access.
• life.dimensionminorStrategic or Co-development PartnerLive communication, event marketing, conventions, congresses, and social media services. Designs individual case materials according to client needs to maximize success and guarantee ROI.
• SpannerwerksminorImplementation/ SI/ Consulting PartnerExperienced project management and subject matter experts in areas like CMC and Manufacturing to help execute throughout the drug development process.
• Value GenomecoreStrategic or Co-development PartnerHelps biopharmaceutical firms maximize access to innovative medicines while optimizing revenue streams. Brings extensive knowledge and practical experience to develop strong pricing, reimbursement and access strategies to ensure reimbursement listing and access for patients.
• Orphan NowcoreStrategic or Co-development PartnerNetwork of independent, highly successful rare disease business leaders and experts focused on supporting orphan drug companies operating within and across Europe. Enables companies to capitalize on experienced in-market senior talent and capabilities early and quickly.
• OrphanDCcoreStrategic or Co-development PartnerPartner for biotech companies and CROs in Latin America. Offers local and global capabilities focused on clinical development services, early access programs, and hosting and distribution. Maintains relationships with government agencies, health ministries, patient advocacy organizations and private institutions in LATAM.
• PrntYardminorImplementation/ SI/ Consulting PartnerVisual messaging firm that blends storytelling and design to articulate client messages. Develops materials - both print and digital - from branding to document design through client presentations.
• BrandsymbolminorImplementation/ SI/ Consulting PartnerSpecialized naming agency navigating complexities of global name development in pharmaceutical and biotech space. Creates world-class brand names, generic (INN/USAN) names, and clinical trial names using data-driven approach to ensure trademark and regulatory approval.
• LGA, LLPcoreImplementation/ SI/ Consulting PartnerPremier New England-based accounting and business advisory firm with collaborative, team-based approach. Serves life science and biotech clients with strategic advisory, tax, outsource accounting, and assurance services. Fractional CFO services available through Steve Sieker.
• Ubie HealthminorStrategic or Co-development PartnerProvides AI-powered patient engagement tools. Ubie's AI Symptom Checker helps more than 10M patients monthly understand their symptoms and connect to appropriate care. Supports patient identification and engagement initiatives.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Eversana: End-to-end commercialization services provider for life sciences companies, spanning market access, patient services, and launch execution. Direct peer to RCP in serving rare disease and specialty biotech clients preparing for and executing product launches.
• ZS Associates: Global management consulting firm with a large pharma and biotech practice focused on commercial strategy, sales, marketing, and market access. Comparable to RCP in targeting life sciences clients for commercial build-out and launch execution, but at much greater scale.
• Trinity Life Sciences: Specialist life sciences strategy and commercialization consultancy serving biotech and pharma with commercial planning, market access, and launch support. Highly comparable to RCP in service offering, customer base (clinical-stage and commercial-stage biotech), and milestone-driven engagement model.
• Axtria: Data analytics and commercial operations consultancy serving pharma and biotech with sales, marketing, and market access capabilities. Overlaps with RCP's commercial operations and analytics offerings, though at significantly larger scale.
• Beghou Consulting: Life sciences consulting firm specializing in commercial strategy, sales, and marketing for biotech and pharma. Comparable in focus on helping emerging biotech build commercial capabilities pre-launch and through early commercialization.

Broad incumbents

• PharmaLex: Global provider of regulatory, quality, and commercialization services for the biopharmaceutical industry. Overlaps with RCP's regulatory affairs and market access offerings, particularly for European and emerging market clients.
• Charles River Associates: Global consulting firm with a life sciences practice covering commercial strategy, pricing, and market access for pharma and biotech. Comparable to RCP in serving as expert advisors on commercial and market access questions, with a far larger footprint.
• McKinsey & Company (Pharma & Medical Products Practice): Top-tier global management consultancy with a dedicated pharma and medical products practice advising biotech on commercial strategy, launch, and market access. Represents the high end of competition for the largest biotech commercialization engagements.
• Syneos Health: Large contract research organization and commercialization services provider for biopharma. RCP's commercialization planning and launch support work overlaps with Syneos' commercial solutions business, though Syneos is a much broader, publicly traded incumbent.

Emerging players

• Indegene: Technology-led commercialization services company for life sciences, combining consulting, digital, and operations. Comparable to RCP in commercial strategy and market access, with stronger technology and offshore delivery capabilities.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/RCPBIO
• LinkedInlinkedin.com/company/rapid-commercialization-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rapid Commercialization Partners